Key takeaways
- In clinical trials without structured training, up to 40% of weight lost on GLP-1 receptor agonists can be lean muscle mass rather than adipose tissue.
- Skeletal muscle is our largest metabolic organ, responsible for over 80% of postprandial glucose disposal and long-term resting metabolic rate.
- Losing muscle during weight loss increases the risk of weight regain, sarcopenia, and metabolic slowdown.
- Averra Life couples all metabolic therapeutics with Styku 3D tracking, targeted resistance protocols, and clinical nutrition approved by a dedicated provider.
The Unintended Consequence of Appetite Suppression
GLP-1 receptor agonists have transformed metabolic medicine by slowing gastric emptying and dampening hunger signaling in the hypothalamus. However, when total caloric intake drops sharply without nutritional planning, the body catabolizes skeletal muscle alongside adipose tissue.
Muscle loss lowers your basal metabolic rate, making it harder to maintain results long term. It also reduces insulin sensitivity, since skeletal muscle is the primary storage site for circulating glucose.
The Averra Clinical Safeguard
At Averra Life, metabolic therapeutics are never prescribed in isolation. Every patient receives a Personal Health Plan with structured dietary protein targets (typically 1.6 to 2.2 grams per kilogram of ideal body weight) and progressive resistance training.
We use medical-grade Styku 3D body composition scanning every 120 days to verify that weight loss is coming from visceral and subcutaneous fat while preserving precious lean mass.
Frequently asked questions
Can I preserve muscle while taking a GLP-1?
Yes. With adequate dietary protein, targeted amino acid supplementation, and consistent resistance training, members can minimize or eliminate muscle loss while shedding body fat.